Search

Your search keyword '"A. A. Taiwo"' showing total 19,243 results
Start Over Author "A. A. Taiwo"
19,243 results on '"A. A. Taiwo"'

52. Correction to: Anticoagulation control among patients on vitamin K antagonists in nine countries in SubSaharan Africa

Author

Mwita, Julius Chacha, Francis, Joel Msafri, Pillay, Chriselda, Ogah, Okechukwu S., Goshu, Yadeta Dejuma, Agyekum, Francis, Musonda, John Mukuka, James, Maduka Chiedozie, Tefera, Endale, Kabo, Tsie, Ditlhabolo, Irene Keolebile, Ndlovu, Kagiso, Ayodele, Ayoola Yekeen, Mikomangwa, Wigilya P., Chillo, Pilly, Damasceno, Albertino, Folson, Aba Ankomaba, Oyekunle, Anthony, Tebuka, Erius, Kalokola, Fredrick, Forrest, Karen, Dunn, Helena, Karaye, Kamilu, Jean-Pierre, Fina Lubaki, Oljira, Chala Fekadu, Assefa, Tamrat, Taiwo, Tolulope Shogade, E.Nwafor, Chibuike, Omole, Olufemi, Anakwue, Raphael, and Cohen, Karen

Published
2024
Full Text
View/download PDF

53. Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial

Author

Jagannathan, Prasanna, Chew, Kara W, Giganti, Mark J, Hughes, Michael D, Moser, Carlee, Main, Mark J, Monk, Phillip D, Javan, Arzhang Cyrus, Li, Jonathan Z, Fletcher, Courtney V, McCarthy, Caitlyn, Wohl, David A, Daar, Eric S, Eron, Joseph J, Currier, Judith S, Singh, Upinder, Smith, Davey M, Fischer, William, Team, ACTIV-2 A5401 Study, Chew, Kara, Smith, David, Daar, Eric, Wohl, David, Currier, Judith, Eron, Joseph, Hughes, Michael, Giganti, Mark, Ritz, Justin, Hosey, Lara, Roa, Jhoanna, Patel, Nilam, Colsh, Kelly, Rwakazina, Irene, Beck, Justine, Sieg, Scott, Li, Jonathan, Fletcher, Courtney, Evering, Teresa, Ignacio, Rachel Bender, Cardoso, Sandra, Corado, Katya, Jilg, Nikolaus, Perelson, Alan, Pillay, Sandy, Riviere, Cynthia, Taiwo, Babafemi, Gottesman, Joan, Newell, Matthew, Pedersen, Susan, Dragavon, Joan, Jennings, Cheryl, Greenfelder, Brian, Murtaugh, William, Kosmyna, Jan, Gapara, Morgan, Shahkolahi, Akbar, Pierone, Gerald, Elliott, Juliana, Jacobson, Jeffrey, Hojat, Leila, Pasternak, Julie, Berardi, Jonathan, Arar, Celine, Bukhman, Yevgeniy, Jain, Manish, Bukhman, Eugene, Shaik, Sadia, Hatlen, Timothy, Dooley, Kelly, Becker, Becky, Wilkins, Adaliah, Pérez, Jose, Roman, Eloy, Fernández, Heriberto, Hoover, Keila, Renfroe, James, Weldon, Mauney, Bougher, Genei, Malvestutto, Carlos, Harber, Heather, Cicarella, Robyn, Neytman, Gene, Herman, Jack, Herman, Craig, Aziz, Mariam, Swiatek, Joan, Pathak, Divya, Choudhary, Madhu, Sullivano, Jennifer, Osiyemi, Olayemi, Izquierdo, Myriam, Torna, Odelsey, Khodabakhshian, Aleen, and Fortier, Samantha

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Coronaviruses, Infectious Diseases, Coronaviruses Therapeutics and Interventions, Emerging Infectious Diseases, Patient Safety, Prevention, Lung, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, Infection, Good Health and Well Being, Inhaled interferon, SARS-CoV-2, COVID-19, ACTIV-2, Randomized clinical trial, ACTIV-2/A5401 Study Team, Clinical sciences, Health services and systems, Public health
Abstract

BackgroundWith the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of novel therapeutics to prevent progression to severe COVID-19 remains a critical need.MethodsSafety, clinical and antiviral efficacy of inhaled interferon-β1a (SNG001) were evaluated in a phase II randomized controlled trial on the ACTIV-2/A5401 platform (ClinicalTrials.govNCT04518410). Adult outpatients with confirmed SARS-CoV-2 infection within 10 days of symptom onset were randomized and initiated either orally inhaled nebulized SNG001 given once daily for 14 days (n = 110) or blinded pooled placebo (n = 110) between February 10 and August 18, 2021.FindingsThe proportion of participants reporting premature treatment discontinuation was 9% among SNG001 and 13% among placebo participants. There were no differences between participants who received SNG001 or placebo in the primary outcomes of treatment emergent Grade 3 or higher adverse events (3.6% and 8.2%, respectively), time to symptom improvement (median 13 and 9 days, respectively), or proportion with unquantifiable nasopharyngeal SARS-CoV-2 RNA at days 3 (28% [26/93] vs. 39% [37/94], respectively), 7 (65% [60/93] vs. 66% [62/94]) and 14 (91% [86/95] vs. 91% [83/81]). There were fewer hospitalizations with SNG001 (n = 1; 1%) compared with placebo (n = 7; 6%), representing an 86% relative risk reduction (p = 0.07). There were no deaths in either arm.InterpretationIn this trial, SNG001 was safe and associated with a non-statistically significant decrease in hospitalization for COVID-19 pneumonia.FundingThe ACTIV-2 platform study is funded by the NIH. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636 and UM1 AI106701. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Published
2023

54. One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial

Author

Jilg, Nikolaus, Chew, Kara W, Giganti, Mark J, Daar, Eric S, Wohl, David A, Javan, Arzhang Cyrus, Kantor, Amy, Moser, Carlee, Coombs, Robert W, Neytman, Gene, Hoover, Keila, Jana, Atasi, Hart, Phil A, Greninger, Alexander L, Szurgot, Bob, Eron, Joseph J, Currier, Judith S, Hughes, Michael D, Smith, Davey M, Li, Jonathan Z, Chew, Kara, Smith, David, Daar, Eric, Wohl, David, Currier, Judith, Eron, Joseph, Hughes, Michael, Giganti, Mark, Ritz, Justin, Hosey, Lara, Roa, Jhoanna, Patel, Nilam, Colsh, Kelly, Rwakazina, Irene, Beck, Justine, Sieg, Scott, Li, Jonathan, Fletcher, Courtney, Fischer, William, Evering, Teresa, Coombs, Robert, Ignacio, Rachel Bender, Cardoso, Sandra, Corado, Katya, Jagannathan, Prasanna, Perelson, Alan, Pillay, Sandy, Riviere, Cynthia, Singh, Upinder, Taiwo, Babafemi, Gottesman, Joan, Newell, Matthew, Pedersen, Susan, Dragavon, Joan, Jennings, Cheryl, Greenfelder, Brian, Murtaugh, William, Kosmyna, Jan, Gapara, Morgan, and Shahkolahi, Akbar

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Emerging Infectious Diseases, Infectious Diseases, Coronaviruses Therapeutics and Interventions, Coronaviruses, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Humans, Adult, COVID-19, SARS-CoV-2, RNA, Viral, Time Factors, Treatment Outcome, camostat, outpatient, phase 2, ACTIV-2/A5401 Study Team, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundCamostat inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vitro. We studied the safety and efficacy of camostat in ACTIV-2/A5401, a phase 2/3 platform trial of therapeutics for COVID-19 in nonhospitalized adults.MethodsWe conducted a phase 2 study in adults with mild-to-moderate COVID-19 randomized to oral camostat for 7 days or a pooled placebo arm. Primary outcomes were time to improvement in COVID-19 symptoms through day 28, proportion of participants with SARS-CoV-2 RNA below the lower limit of quantification (LLoQ) from nasopharyngeal swabs through day 14, and grade ≥3 treatment-emergent adverse events (TEAEs) through day 28.ResultsOf 216 participants (109 randomized to camostat, 107 to placebo) who initiated study intervention, 45% reported ≤5 days of symptoms at study entry and 26% met the protocol definition of higher risk of progression to severe COVID-19. Median age was 37 years. Median time to symptom improvement was 9 days in both arms (P = .99). There were no significant differences in the proportion of participants with SARS-CoV-2 RNA ConclusionsIn a phase 2 study of nonhospitalized adults with mild-to-moderate COVID-19, oral camostat did not accelerate viral clearance or time to symptom improvement, or reduce hospitalizations or deaths. Clinical Trials Registration. ClinicalTrials.gov identifier: NCT04518410.

Published
2023

55. Food Insecurity Disparities Among Immigrants in the U.S.

Author

Sharareh, Nasser, Adesoba, Taiwo, Wallace, Andrea, Hess, Rachel, Wilson, Fernando, and Seligman, Hilary

Subjects
Immigrants, food insecurity, health policy, public health, socioeconomic factors
Abstract

INTRODUCTION: Food insecurity negatively impacts public health and costs the U.S. healthcare system $53 billion annually. Immigrants are at higher risk of food insecurity. We sought to (1) characterize the prevalence of food insecurity among immigrants (i.e., noncitizens and naturalized citizens) and U.S.-born citizens and (2) determine whether Supplemental Nutrition Assistance Program utilization and income-poverty ratio levels impact the relationship between immigration status and food insecurity. METHODS: Multivariable logistic regression models were used to determine the odds of food insecurity (dependent variables) using nationally representative data from the 2019-2020 National Health Interview Survey. Independent variables included immigration status, Supplemental Nutrition Assistance Program utilization, income-poverty ratio, and other important demographics. AORs with their 95% CIs are reported. Analysis was conducted in 2022. RESULTS: After controlling for independent variables, noncitizens had 1.28 (95% CI=1.02, 1.61) times higher odds of food insecurity than U.S.-born citizens. There was no food insecurity disparity between naturalized citizens and U.S.-born citizens. However, the association between immigration status and food insecurity varied significantly at different levels of Supplemental Nutrition Assistance Program utilization and income-poverty ratio. There were no food insecurity disparities between immigrants and U.S.-born citizens when they utilized the Supplemental Nutrition Assistance Program and when they had an income below 200% federal poverty level. Noncitizens who did not utilize the Supplemental Nutrition Assistance Program or those with an income above 200% federal poverty level were more likely to report food insecurity than their U.S.-born counterparts (AOR=1.32, 95% CI=1.01, 1.73 and AOR=1.88, 95% CI=1.24, 2.86, respectively). Moreover, naturalized citizens with an income above 200% federal poverty level were also more likely to report food insecurity than their U.S.-born counterparts (AOR=1.61, 95% CI=1.21, 2.14). CONCLUSIONS: Supplemental Nutrition Assistance Program utilization may likely eliminate food insecurity disparities among immigrants and U.S.-born citizens. However, among non-Supplemental Nutrition Assistance Program utilizers, significant food insecurity disparities remained between noncitizens and U.S.-born citizens after adjusting for independent variables. In addition, among individuals with incomes above 200% federal poverty level, significant food insecurity disparities were observed between immigrants and U.S.-born citizens. More research is needed to further understand the role that fear of deportation, ineligibility or lack of awareness about eligibility for the Supplemental Nutrition Assistance Program, and other factors such as structural racism play in food insecurity disparities between immigrants and U.S.-born citizens.

Published
2023

78. Author Correction: Incidence of postpartum depression among women with postpartum haemorrhage in Kano, northern Nigeria

Author

Tsiga-Ahmed, Fatimah Isma’il, Umar, Musa Usman, Adamu, Aishatu Lawal, Sulaiman, Sahabi Kabir, Gboluwaga, Amole Taiwo, Jalo, Rabiu Ibrahim, Ibrahim, Usman Muhammad, Ayaba, Aminatu Kwaku, Ahmed, Zainab Datti, Sunusi, Surayya Murtala, Abdullahi, Nafisat Tijjjani, Kabir, Hajara Shehu, Abu, Stephen Mohammed, and Galadanci, Hadiza Shehu

Published
2024
Full Text
View/download PDF

89. mRNA vaccine design for Epstein–Barr virus: an immunoinformatic approach

Author

Oladipo, Elijah Kolawole, Akinleye, Temitope Michael, Adeyemo, Stephen Feranmi, Akinboade, Modinat Wuraola, Siyanbola, Kehinde Favour, Adetunji, Victoria Ademide, Arowosegbe, Olukayode Abimbola, Olatunji, Victoria Kehinde, Adaramola, Esther Oluwadarasimi, Afolabi, Hezekiah Omotayo, Ajani, Christianah Damilola, Siyanbola, Taiwo Pleasure, Folakanmi, Elizabeth Oluwatoyin, Irewolede, Boluwatife Ayobami, Okesanya, Olalekan John, Ajani, Olumide Faith, Ariyo, Olumuyiwa Elijah, Jimah, Esther Moradeyo, Iwalokun, Bamidele Abiodun, Kolawole, Olatunji Matthew, Oloke, Julius Kola, and Onyeaka, Helen

Published
2024
Full Text
View/download PDF

90. Exploring the nuclear proteins, viral capsid protein, and early antigen protein using immunoinformatic and molecular modeling approaches to design a vaccine candidate against Epstein Barr virus

Author

Oladipo, Elijah Kolawole, Ojo, Taiwo Ooreoluwa, Elegbeleye, Oluwabamise Emmanuel, Bolaji, Olawale Quadri, Oyewole, Moyosoluwa Precious, Ogunlana, Abdeen Tunde, Olalekan, Emmanuel Obanijesu, Abiodun, Bamidele, Adediran, Daniel Adewole, Obideyi, Oluwaseun Adeola, Olufemi, Seun Elijah, Salamatullah, Ahmad Mohammad, Bourhia, Mohammed, Younous, Youssouf Ali, and Adelusi, Temitope Isaac

Published
2024
Full Text
View/download PDF

96. Physical and insecticidal durability of Interceptor®, Interceptor® G2, and PermaNet® 3.0 insecticide-treated nets in Burkina Faso: results of durability monitoring in three sites from 2019 to 2022

Author

Raharinjatovo, Jacky, Dabiré, Roch Kounbobr, Esch, Keith, Soma, Dieudonné Diloma, Hien, Aristide, Camara, Tiecoura, Diouf, Mame Birame, Belemvire, Allison, Gerberg, Lilia, Awolola, Taiwo Samson, Koné, Adama, Jacob, Djenam, Vandecandelaere, Sophie, Baes, Marie, and Poyer, Stephen

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results